UNSPSC 41181521: C-reactive protein immunological test system

In this classification, a C-reactive protein immunological test system is a device that consists of the reagents used to identify by immunochemical techniques C-reactive protein. US FDA regulates C-reactive protein immunological test system under 21 CFR 866.5270 and under FDA product code DCN.

UNSPSC 41181521 C-reactive protein immunological test system is a Commodity code, but recent state and local procurement activity tagged under this code shows minimal alignment with the nominal scope. The source records ten recent opportunities spanning August 2026 through October 2026, with only one—Marion County, Oregon's laboratory testing services and phlebotomy solicitation—touching immunological or clinical testing work. The remaining nine opportunities address spectrophotometers, optical profilers, electrical test equipment, software licenses, atmospheric monitoring, brake testers, landscape engineering, and equipment repair services. These are discrete pieces of laboratory and utility infrastructure, not clinical diagnostic systems or immunological reagent supply. The mismatch suggests either systematic miscoding of opportunities in state procurement systems or that this Commodity code is not actively used for its stated purpose in current state and local contracting.

The single plausibly relevant opportunity is Marion County, Oregon's ITB SO1814-26 (due July 24, 2026) for laboratory testing services and phlebotomy for Adults in Custody, which includes specimen collection and test reporting. The remaining solicitations are driven by discrete equipment needs at universities (Texas State, Jackson State, Texas A&M), utilities (Ocala Electric, Kissimmee Utility Authority, Lee County Port Authority, Lubbock Power & Light, City of Tampa Water), and other local bodies (Colorado State Patrol, City of Phoenix), with no pattern suggesting a pipeline of state or local investment in immunological diagnostic platforms or C-reactive protein test systems. Issuers are scattered across Texas, Florida, Oregon, Colorado, and Arizona with no geographic concentration. Given the sparse and divergent activity, this code presents limited near-term procurement opportunity for vendors in the clinical diagnostics or immunological testing space.